A Phase I clinical trial was completed using CD19-41BB-TCRζ CAR NK cells to target B-lineage acute lymphoblastic leukemia (ALL) malignancy (NCT00995137). This evidence concerns the gene CD247 and acute lymphoblastic leukemia.